Abstract
Abstract As target-carrier, holotransferrin (Tf) was conjugated with dihydroartemisinin (DHA) to form a new targeted drug. An analog of DHA, 4-(12-dihydroartemisininoxy) benzoic acid hydrazide (DBAH) have been synthesized and characterized by UV/vis spectroscopy, IR spectroscopy, NMR, and electrochemistry. Periodate was used to oxidize hydroxy groups on the N-glycoside chains of C-domain on Tf surface, and then DBAH reacted with the oxidized Tf to form a covalent conjugate. In addition, this targeted drug was characterized by UV/vis spectroscopy and electrochemistry. Methyl thiazolyl tetrazolium (MTT) assay was used to evaluate the killing effect of DBAH-Tf on MCF-7 and human normal breast cells. The results showed that DBAH-Tf was 286 times more potent in killing MCF-7 cells than normal cells, which implied that DBAH-Tf could target the cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
